{"id":"dag181","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DAG181 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing interaction with PD-1 on T cells. This blockade restores T cell activation, proliferation, and cytotoxic function, allowing the immune system to recognize and eliminate cancer cells. The mechanism is similar to other PD-L1 checkpoint inhibitors used in oncology.","oneSentence":"DAG181 is a humanized monoclonal antibody that targets and blocks PD-L1, enhancing anti-tumor immune responses by releasing the PD-1/PD-L1 checkpoint inhibition.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:08:34.126Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT04565171","phase":"PHASE1","title":"Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2021-04-15","conditions":"Renal Impairment","enrollment":16},{"nctId":"NCT03593447","phase":"PHASE2","title":"To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients","status":"COMPLETED","sponsor":"Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.","startDate":"2018-03-15","conditions":"Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic, Cirrhosis","enrollment":133},{"nctId":"NCT04155515","phase":"PHASE3","title":"A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients","status":"COMPLETED","sponsor":"Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.","startDate":"2019-06-13","conditions":"Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic, Cirrhosis","enrollment":370},{"nctId":"NCT03458481","phase":"PHASE2","title":"Phase 2 Study of Yimitasvir Phosphate Capsules","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2017-07-31","conditions":"Chronic HCV Infection","enrollment":129},{"nctId":"NCT03487107","phase":"PHASE3","title":"Phase 3 Study of Yimitasvir Phosphate Capsules","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2018-04-17","conditions":"Chronic HCV Infection","enrollment":362},{"nctId":"NCT03610880","phase":"PHASE1","title":"To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.","startDate":"2017-10-17","conditions":"Healthy Chinese Volunteers","enrollment":24},{"nctId":"NCT03462173","phase":"PHASE1","title":"The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2014-12-03","conditions":"Chronic Hepatitis c","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Yimitasvir"],"phase":"phase_3","status":"active","brandName":"DAG181","genericName":"DAG181","companyName":"Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.","companyId":"dongguan-hec-taigen-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DAG181 is a humanized monoclonal antibody that targets and blocks PD-L1, enhancing anti-tumor immune responses by releasing the PD-1/PD-L1 checkpoint inhibition. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}